FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022292022> ?p ?o ?g. }

• W2022292022 endingPage "1688" @default.
• W2022292022 startingPage "1685" @default.
• W2022292022 abstract "Background: Patient survival with the acquired immune deficiency syndrome (AIDS) and cytomegalovirus (CMV) retinitis is increasing because of earlier diagnosis and improved medical therapy. Visual morbidity that occurs with prolonged survival has not been well described. Methods: To evaluate the progression of retinitis, ocular complications, and visual morbidity, the authors retrospectively reviewed the records of 22 patients who had tested positive for human immunodeficiency virus since December 31, 1987. Each patient had an ophthalmologic diagnosis of CMV retinitis and had survived for a minimum of 6 months after diagnosis of retinitis. Patients were treated with intravenous ganciclovir alone, ganciclovir followed by foscarnet, or foscarnet alone (1 patient). Results: Mean survival was 16.7 months after the diagnosis of retinitis. The retinitis progressed in 74% of eyes during therapy. Visual acuity of 20/70 or worse occurred in 79% of eyes at a mean of 7.6 months from diagnosis of CMV retinitis. No light perception occurred in 49% of eyes after a mean of 15 months patient survival. Eleven patients with visual acuity of 20/70 or worse in both eyes survived a mean of 11 months. In 39 eyes with CMV retinitis, the following complications occurred: retinal detachment (33%), papillitis (32%), branch retinal artery occlusion (10%), persistent iritis (5%), and cataract (2.5%). Conclusion: Improved modalities of therapy will continue to increase the survival of patients with AIDS and CMV retinitis. Progression of the retinitis occurs with current therapeutic regimens in the majority of patients. As survival increases, significant visual loss and ocular complications may compromise patient care and quality of life. Background: Patient survival with the acquired immune deficiency syndrome (AIDS) and cytomegalovirus (CMV) retinitis is increasing because of earlier diagnosis and improved medical therapy. Visual morbidity that occurs with prolonged survival has not been well described. Methods: To evaluate the progression of retinitis, ocular complications, and visual morbidity, the authors retrospectively reviewed the records of 22 patients who had tested positive for human immunodeficiency virus since December 31, 1987. Each patient had an ophthalmologic diagnosis of CMV retinitis and had survived for a minimum of 6 months after diagnosis of retinitis. Patients were treated with intravenous ganciclovir alone, ganciclovir followed by foscarnet, or foscarnet alone (1 patient). Results: Mean survival was 16.7 months after the diagnosis of retinitis. The retinitis progressed in 74% of eyes during therapy. Visual acuity of 20/70 or worse occurred in 79% of eyes at a mean of 7.6 months from diagnosis of CMV retinitis. No light perception occurred in 49% of eyes after a mean of 15 months patient survival. Eleven patients with visual acuity of 20/70 or worse in both eyes survived a mean of 11 months. In 39 eyes with CMV retinitis, the following complications occurred: retinal detachment (33%), papillitis (32%), branch retinal artery occlusion (10%), persistent iritis (5%), and cataract (2.5%). Conclusion: Improved modalities of therapy will continue to increase the survival of patients with AIDS and CMV retinitis. Progression of the retinitis occurs with current therapeutic regimens in the majority of patients. As survival increases, significant visual loss and ocular complications may compromise patient care and quality of life." @default.
• W2022292022 created "2016-06-24" @default.
• W2022292022 creator A5045213164 @default.
• W2022292022 creator A5065545205 @default.
• W2022292022 creator A5091672269 @default.
• W2022292022 date "1993-11-01" @default.
• W2022292022 modified "2023-10-18" @default.
• W2022292022 title "Long-term Visual Morbidity of Cytomegalovirus Retinitis in Patients with Acquired Immune Deficiency Syndrome" @default.
• W2022292022 cites W138405929 @default.
• W2022292022 cites W1969151374 @default.
• W2022292022 cites W1969731543 @default.
• W2022292022 cites W1969909913 @default.
• W2022292022 cites W1981156436 @default.
• W2022292022 cites W1982079405 @default.
• W2022292022 cites W1984791309 @default.
• W2022292022 cites W1993433202 @default.
• W2022292022 cites W1995111831 @default.
• W2022292022 cites W1999080046 @default.
• W2022292022 cites W2005165933 @default.
• W2022292022 cites W2016872968 @default.
• W2022292022 cites W2019849985 @default.
• W2022292022 cites W2028541088 @default.
• W2022292022 cites W2030460966 @default.
• W2022292022 cites W2064508760 @default.
• W2022292022 cites W2066628634 @default.
• W2022292022 cites W2083391908 @default.
• W2022292022 cites W2090916141 @default.
• W2022292022 cites W2095729328 @default.
• W2022292022 cites W2101969982 @default.
• W2022292022 cites W2133664045 @default.
• W2022292022 cites W2597824021 @default.
• W2022292022 cites W2616647315 @default.
• W2022292022 cites W4242511899 @default.
• W2022292022 doi "https://doi.org/10.1016/s0161-6420(93)31417-x" @default.
• W2022292022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8233395" @default.
• W2022292022 hasPublicationYear "1993" @default.
• W2022292022 type Work @default.
• W2022292022 sameAs 2022292022 @default.
• W2022292022 citedByCount "35" @default.
• W2022292022 countsByYear W20222920222013 @default.
• W2022292022 countsByYear W20222920222014 @default.
• W2022292022 countsByYear W20222920222016 @default.
• W2022292022 countsByYear W20222920222019 @default.
• W2022292022 crossrefType "journal-article" @default.
• W2022292022 hasAuthorship W2022292022A5045213164 @default.
• W2022292022 hasAuthorship W2022292022A5065545205 @default.
• W2022292022 hasAuthorship W2022292022A5091672269 @default.
• W2022292022 hasConcept C118487528 @default.
• W2022292022 hasConcept C141071460 @default.
• W2022292022 hasConcept C203014093 @default.
• W2022292022 hasConcept C2522874641 @default.
• W2022292022 hasConcept C2776724271 @default.
• W2022292022 hasConcept C2777016524 @default.
• W2022292022 hasConcept C2777324356 @default.
• W2022292022 hasConcept C2777965375 @default.
• W2022292022 hasConcept C2778257484 @default.
• W2022292022 hasConcept C2779820661 @default.
• W2022292022 hasConcept C71924100 @default.
• W2022292022 hasConceptScore W2022292022C118487528 @default.
• W2022292022 hasConceptScore W2022292022C141071460 @default.
• W2022292022 hasConceptScore W2022292022C203014093 @default.
• W2022292022 hasConceptScore W2022292022C2522874641 @default.
• W2022292022 hasConceptScore W2022292022C2776724271 @default.
• W2022292022 hasConceptScore W2022292022C2777016524 @default.
• W2022292022 hasConceptScore W2022292022C2777324356 @default.
• W2022292022 hasConceptScore W2022292022C2777965375 @default.
• W2022292022 hasConceptScore W2022292022C2778257484 @default.
• W2022292022 hasConceptScore W2022292022C2779820661 @default.
• W2022292022 hasConceptScore W2022292022C71924100 @default.
• W2022292022 hasIssue "11" @default.
• W2022292022 hasLocation W20222920221 @default.
• W2022292022 hasLocation W20222920222 @default.
• W2022292022 hasOpenAccess W2022292022 @default.
• W2022292022 hasPrimaryLocation W20222920221 @default.
• W2022292022 hasRelatedWork W1527433087 @default.
• W2022292022 hasRelatedWork W1979471217 @default.
• W2022292022 hasRelatedWork W1984817366 @default.
• W2022292022 hasRelatedWork W2008736461 @default.
• W2022292022 hasRelatedWork W2031029683 @default.
• W2022292022 hasRelatedWork W2066480953 @default.
• W2022292022 hasRelatedWork W2338748953 @default.
• W2022292022 hasRelatedWork W2403997462 @default.
• W2022292022 hasRelatedWork W2759923021 @default.
• W2022292022 hasRelatedWork W2977627627 @default.
• W2022292022 hasVolume "100" @default.
• W2022292022 isParatext "false" @default.
• W2022292022 isRetracted "false" @default.
• W2022292022 magId "2022292022" @default.
• W2022292022 workType "article" @default.